ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

Finally, An FY01 Appropriation For NIH; NCI’s Share $3.757 Billion, A 13.5% Raise.

January 5, 2001

$3.3 Million For Retinoid Contract Awarded

October 14, 1977

FDA: Silicone Breast Implants Safe, But Not “Lifetime Device”

June 24, 2011

New Guidelines Developed For Cooperative Group Grant Review

August 17, 1979

Also NY State Initiatives Would Fund Research Using I-ELCAP Protocol for CT Scanning for Lung Cancer.

May 4, 2007

Biomedical Panel To Hear Public At Sept. Meeting

July 11, 1975